· Periodic Report
Q3 revenue KRW 51.4 billion, operating loss of KRW 3.19 billion
Samil Pharmaceutical sold KRW 51.4 billion in Q3 and lost KRW 3.19 billion from its main business, versus sales of KRW 51.2 billion and a loss of KRW 5.15 billion a year earlier.